Cargando…

Diagnosis, Prognosis, and Treatment of Canine Hemangiosarcoma: A Review Based on a Consensus Organized by the Brazilian Association of Veterinary Oncology, ABROVET

SIMPLE SUMMARY: Hemangiosarcoma is a mesenchymal neoplasm that originates in the endothelial cells of blood vessels. According to the location of origin, they can be classified as non-visceral and visceral types. Hemangiosarcoma can be very aggressive and metastasize to distant organs. The aim of th...

Descripción completa

Detalles Bibliográficos
Autores principales: De Nardi, Andrigo Barboza, de Oliveira Massoco Salles Gomes, Cristina, Fonseca-Alves, Carlos Eduardo, de Paiva, Felipe Noleto, Linhares, Laís Calazans Menescal, Carra, Gabriel João Unger, dos Santos Horta, Rodrigo, Ruiz Sueiro, Felipe Augusto, Jark, Paulo Cesar, Nishiya, Adriana Tomoko, de Carvalho Vasconcellos, Carmen Helena, Ubukata, Rodrigo, Batschinski, Karen, Sobral, Renata Afonso, Fernandes, Simone Crestoni, Biondi, Luiz Roberto, De Francisco Strefezzi, Ricardo, Matera, Julia Maria, Rangel, Marcelo Monte Mor, dos Anjos, Denner Santos, Brunner, Carlos Henrique Maciel, Laufer-Amorim, Renee, Cadrobbi, Karine Germano, Cirillo, Juliana Vieira, Martins, Mauro Caldas, de Paula Reis Filho, Nazilton, Silva Lessa, Diego Fernando, Portela, Roberta, Scarpa Carneiro, Carolina, Ricci Lucas, Sílvia Regina, Fukumasu, Heidge, Feliciano, Marcus Antônio Rossi, Gomes Quitzan, Juliany, Dagli, Maria Lucia Zaidan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10093745/
https://www.ncbi.nlm.nih.gov/pubmed/37046686
http://dx.doi.org/10.3390/cancers15072025
_version_ 1785023660089671680
author De Nardi, Andrigo Barboza
de Oliveira Massoco Salles Gomes, Cristina
Fonseca-Alves, Carlos Eduardo
de Paiva, Felipe Noleto
Linhares, Laís Calazans Menescal
Carra, Gabriel João Unger
dos Santos Horta, Rodrigo
Ruiz Sueiro, Felipe Augusto
Jark, Paulo Cesar
Nishiya, Adriana Tomoko
de Carvalho Vasconcellos, Carmen Helena
Ubukata, Rodrigo
Batschinski, Karen
Sobral, Renata Afonso
Fernandes, Simone Crestoni
Biondi, Luiz Roberto
De Francisco Strefezzi, Ricardo
Matera, Julia Maria
Rangel, Marcelo Monte Mor
dos Anjos, Denner Santos
Brunner, Carlos Henrique Maciel
Laufer-Amorim, Renee
Cadrobbi, Karine Germano
Cirillo, Juliana Vieira
Martins, Mauro Caldas
de Paula Reis Filho, Nazilton
Silva Lessa, Diego Fernando
Portela, Roberta
Scarpa Carneiro, Carolina
Ricci Lucas, Sílvia Regina
Fukumasu, Heidge
Feliciano, Marcus Antônio Rossi
Gomes Quitzan, Juliany
Dagli, Maria Lucia Zaidan
author_facet De Nardi, Andrigo Barboza
de Oliveira Massoco Salles Gomes, Cristina
Fonseca-Alves, Carlos Eduardo
de Paiva, Felipe Noleto
Linhares, Laís Calazans Menescal
Carra, Gabriel João Unger
dos Santos Horta, Rodrigo
Ruiz Sueiro, Felipe Augusto
Jark, Paulo Cesar
Nishiya, Adriana Tomoko
de Carvalho Vasconcellos, Carmen Helena
Ubukata, Rodrigo
Batschinski, Karen
Sobral, Renata Afonso
Fernandes, Simone Crestoni
Biondi, Luiz Roberto
De Francisco Strefezzi, Ricardo
Matera, Julia Maria
Rangel, Marcelo Monte Mor
dos Anjos, Denner Santos
Brunner, Carlos Henrique Maciel
Laufer-Amorim, Renee
Cadrobbi, Karine Germano
Cirillo, Juliana Vieira
Martins, Mauro Caldas
de Paula Reis Filho, Nazilton
Silva Lessa, Diego Fernando
Portela, Roberta
Scarpa Carneiro, Carolina
Ricci Lucas, Sílvia Regina
Fukumasu, Heidge
Feliciano, Marcus Antônio Rossi
Gomes Quitzan, Juliany
Dagli, Maria Lucia Zaidan
author_sort De Nardi, Andrigo Barboza
collection PubMed
description SIMPLE SUMMARY: Hemangiosarcoma is a mesenchymal neoplasm that originates in the endothelial cells of blood vessels. According to the location of origin, they can be classified as non-visceral and visceral types. Hemangiosarcoma can be very aggressive and metastasize to distant organs. The aim of this critical review is to present data on the epidemiology, etiology, diagnosis, staging, therapeutic modalities, and prognosis of canine hemangiosarcoma based on a consensus meeting organized by the Brazilian Association of Veterinary Oncology (ABROVET) in September 2022. Recent information from the literature, as well as new results from consensus participants, are presented and discussed. ABSTRACT: Hemangiosarcoma is a mesenchymal neoplasm originating in the endothelial cells of blood vessels; they can be classified as non-visceral and visceral types. Non-visceral hemangiosarcomas can affect the skin, subcutaneous tissues, and muscle tissues; visceral hemangiosarcomas can affect the spleen, liver, heart, lungs, kidneys, oral cavity, bones, bladder, uterus, tongue, and retroperitoneum. Among domestic species, dogs are most affected by cutaneous HSA. Cutaneous HSA represents approximately 14% of all HSA diagnosed in this species and less than 5% of dermal tumors, according to North American studies. However, Brazilian epidemiological data demonstrate a higher prevalence, which may represent 27 to 80% of all canine HSAs and 13.9% of all skin neoplasms diagnosed in this species. Cutaneous HSA most commonly affects middle-aged to elderly dogs (between 8 and 15 years old), with no gender predisposition for either the actinic or non-actinic forms. The higher prevalence of cutaneous HSA in some canine breeds is related to lower protection from solar radiation, as low skin pigmentation and hair coverage lead to greater sun exposure. Actinic changes, such as solar dermatosis, are frequent in these patients, confirming the influence of solar radiation on the development of this neoplasm. There are multiple clinical manifestations of hemangiosarcoma in canines. The diagnostic approach and staging classification of cutaneous HSAs are similar between the different subtypes. The definitive diagnosis is obtained through histopathological analysis of incisional or excisional biopsies. Cytology can be used as a presurgical screening test; however, it has little diagnostic utility in cases of HSA because there is a high risk of blood contamination and sample hemodilution. Surgery is generally the treatment of choice for dogs with localized non-visceral HSA without evidence of metastatic disease. Recently, electrochemotherapy (ECT) has emerged as an alternative therapy for the local ablative treatment of different neoplastic types; the use of radiotherapy for the treatment of dogs with cutaneous HSA is uncommon. There is greater consensus in the literature regarding the indications for adjuvant chemotherapy in subcutaneous and muscular HSA; doxorubicin is the most frequently used antineoplastic agent for subcutaneous and muscular subtypes and can be administered alone or in combination with other drugs. Other therapies include antiangiogenic therapy, photodynamic therapy, the association of chemotherapy with the metronomic dose, targeted therapies, and natural products. The benefits of these therapies are presented and discussed. In general, the prognosis of splenic and cardiac HSA is unfavorable. As a challenging neoplasm, studies of new protocols and treatment modalities are necessary to control this aggressive disease.
format Online
Article
Text
id pubmed-10093745
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-100937452023-04-13 Diagnosis, Prognosis, and Treatment of Canine Hemangiosarcoma: A Review Based on a Consensus Organized by the Brazilian Association of Veterinary Oncology, ABROVET De Nardi, Andrigo Barboza de Oliveira Massoco Salles Gomes, Cristina Fonseca-Alves, Carlos Eduardo de Paiva, Felipe Noleto Linhares, Laís Calazans Menescal Carra, Gabriel João Unger dos Santos Horta, Rodrigo Ruiz Sueiro, Felipe Augusto Jark, Paulo Cesar Nishiya, Adriana Tomoko de Carvalho Vasconcellos, Carmen Helena Ubukata, Rodrigo Batschinski, Karen Sobral, Renata Afonso Fernandes, Simone Crestoni Biondi, Luiz Roberto De Francisco Strefezzi, Ricardo Matera, Julia Maria Rangel, Marcelo Monte Mor dos Anjos, Denner Santos Brunner, Carlos Henrique Maciel Laufer-Amorim, Renee Cadrobbi, Karine Germano Cirillo, Juliana Vieira Martins, Mauro Caldas de Paula Reis Filho, Nazilton Silva Lessa, Diego Fernando Portela, Roberta Scarpa Carneiro, Carolina Ricci Lucas, Sílvia Regina Fukumasu, Heidge Feliciano, Marcus Antônio Rossi Gomes Quitzan, Juliany Dagli, Maria Lucia Zaidan Cancers (Basel) Review SIMPLE SUMMARY: Hemangiosarcoma is a mesenchymal neoplasm that originates in the endothelial cells of blood vessels. According to the location of origin, they can be classified as non-visceral and visceral types. Hemangiosarcoma can be very aggressive and metastasize to distant organs. The aim of this critical review is to present data on the epidemiology, etiology, diagnosis, staging, therapeutic modalities, and prognosis of canine hemangiosarcoma based on a consensus meeting organized by the Brazilian Association of Veterinary Oncology (ABROVET) in September 2022. Recent information from the literature, as well as new results from consensus participants, are presented and discussed. ABSTRACT: Hemangiosarcoma is a mesenchymal neoplasm originating in the endothelial cells of blood vessels; they can be classified as non-visceral and visceral types. Non-visceral hemangiosarcomas can affect the skin, subcutaneous tissues, and muscle tissues; visceral hemangiosarcomas can affect the spleen, liver, heart, lungs, kidneys, oral cavity, bones, bladder, uterus, tongue, and retroperitoneum. Among domestic species, dogs are most affected by cutaneous HSA. Cutaneous HSA represents approximately 14% of all HSA diagnosed in this species and less than 5% of dermal tumors, according to North American studies. However, Brazilian epidemiological data demonstrate a higher prevalence, which may represent 27 to 80% of all canine HSAs and 13.9% of all skin neoplasms diagnosed in this species. Cutaneous HSA most commonly affects middle-aged to elderly dogs (between 8 and 15 years old), with no gender predisposition for either the actinic or non-actinic forms. The higher prevalence of cutaneous HSA in some canine breeds is related to lower protection from solar radiation, as low skin pigmentation and hair coverage lead to greater sun exposure. Actinic changes, such as solar dermatosis, are frequent in these patients, confirming the influence of solar radiation on the development of this neoplasm. There are multiple clinical manifestations of hemangiosarcoma in canines. The diagnostic approach and staging classification of cutaneous HSAs are similar between the different subtypes. The definitive diagnosis is obtained through histopathological analysis of incisional or excisional biopsies. Cytology can be used as a presurgical screening test; however, it has little diagnostic utility in cases of HSA because there is a high risk of blood contamination and sample hemodilution. Surgery is generally the treatment of choice for dogs with localized non-visceral HSA without evidence of metastatic disease. Recently, electrochemotherapy (ECT) has emerged as an alternative therapy for the local ablative treatment of different neoplastic types; the use of radiotherapy for the treatment of dogs with cutaneous HSA is uncommon. There is greater consensus in the literature regarding the indications for adjuvant chemotherapy in subcutaneous and muscular HSA; doxorubicin is the most frequently used antineoplastic agent for subcutaneous and muscular subtypes and can be administered alone or in combination with other drugs. Other therapies include antiangiogenic therapy, photodynamic therapy, the association of chemotherapy with the metronomic dose, targeted therapies, and natural products. The benefits of these therapies are presented and discussed. In general, the prognosis of splenic and cardiac HSA is unfavorable. As a challenging neoplasm, studies of new protocols and treatment modalities are necessary to control this aggressive disease. MDPI 2023-03-29 /pmc/articles/PMC10093745/ /pubmed/37046686 http://dx.doi.org/10.3390/cancers15072025 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
De Nardi, Andrigo Barboza
de Oliveira Massoco Salles Gomes, Cristina
Fonseca-Alves, Carlos Eduardo
de Paiva, Felipe Noleto
Linhares, Laís Calazans Menescal
Carra, Gabriel João Unger
dos Santos Horta, Rodrigo
Ruiz Sueiro, Felipe Augusto
Jark, Paulo Cesar
Nishiya, Adriana Tomoko
de Carvalho Vasconcellos, Carmen Helena
Ubukata, Rodrigo
Batschinski, Karen
Sobral, Renata Afonso
Fernandes, Simone Crestoni
Biondi, Luiz Roberto
De Francisco Strefezzi, Ricardo
Matera, Julia Maria
Rangel, Marcelo Monte Mor
dos Anjos, Denner Santos
Brunner, Carlos Henrique Maciel
Laufer-Amorim, Renee
Cadrobbi, Karine Germano
Cirillo, Juliana Vieira
Martins, Mauro Caldas
de Paula Reis Filho, Nazilton
Silva Lessa, Diego Fernando
Portela, Roberta
Scarpa Carneiro, Carolina
Ricci Lucas, Sílvia Regina
Fukumasu, Heidge
Feliciano, Marcus Antônio Rossi
Gomes Quitzan, Juliany
Dagli, Maria Lucia Zaidan
Diagnosis, Prognosis, and Treatment of Canine Hemangiosarcoma: A Review Based on a Consensus Organized by the Brazilian Association of Veterinary Oncology, ABROVET
title Diagnosis, Prognosis, and Treatment of Canine Hemangiosarcoma: A Review Based on a Consensus Organized by the Brazilian Association of Veterinary Oncology, ABROVET
title_full Diagnosis, Prognosis, and Treatment of Canine Hemangiosarcoma: A Review Based on a Consensus Organized by the Brazilian Association of Veterinary Oncology, ABROVET
title_fullStr Diagnosis, Prognosis, and Treatment of Canine Hemangiosarcoma: A Review Based on a Consensus Organized by the Brazilian Association of Veterinary Oncology, ABROVET
title_full_unstemmed Diagnosis, Prognosis, and Treatment of Canine Hemangiosarcoma: A Review Based on a Consensus Organized by the Brazilian Association of Veterinary Oncology, ABROVET
title_short Diagnosis, Prognosis, and Treatment of Canine Hemangiosarcoma: A Review Based on a Consensus Organized by the Brazilian Association of Veterinary Oncology, ABROVET
title_sort diagnosis, prognosis, and treatment of canine hemangiosarcoma: a review based on a consensus organized by the brazilian association of veterinary oncology, abrovet
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10093745/
https://www.ncbi.nlm.nih.gov/pubmed/37046686
http://dx.doi.org/10.3390/cancers15072025
work_keys_str_mv AT denardiandrigobarboza diagnosisprognosisandtreatmentofcaninehemangiosarcomaareviewbasedonaconsensusorganizedbythebrazilianassociationofveterinaryoncologyabrovet
AT deoliveiramassocosallesgomescristina diagnosisprognosisandtreatmentofcaninehemangiosarcomaareviewbasedonaconsensusorganizedbythebrazilianassociationofveterinaryoncologyabrovet
AT fonsecaalvescarloseduardo diagnosisprognosisandtreatmentofcaninehemangiosarcomaareviewbasedonaconsensusorganizedbythebrazilianassociationofveterinaryoncologyabrovet
AT depaivafelipenoleto diagnosisprognosisandtreatmentofcaninehemangiosarcomaareviewbasedonaconsensusorganizedbythebrazilianassociationofveterinaryoncologyabrovet
AT linhareslaiscalazansmenescal diagnosisprognosisandtreatmentofcaninehemangiosarcomaareviewbasedonaconsensusorganizedbythebrazilianassociationofveterinaryoncologyabrovet
AT carragabrieljoaounger diagnosisprognosisandtreatmentofcaninehemangiosarcomaareviewbasedonaconsensusorganizedbythebrazilianassociationofveterinaryoncologyabrovet
AT dossantoshortarodrigo diagnosisprognosisandtreatmentofcaninehemangiosarcomaareviewbasedonaconsensusorganizedbythebrazilianassociationofveterinaryoncologyabrovet
AT ruizsueirofelipeaugusto diagnosisprognosisandtreatmentofcaninehemangiosarcomaareviewbasedonaconsensusorganizedbythebrazilianassociationofveterinaryoncologyabrovet
AT jarkpaulocesar diagnosisprognosisandtreatmentofcaninehemangiosarcomaareviewbasedonaconsensusorganizedbythebrazilianassociationofveterinaryoncologyabrovet
AT nishiyaadrianatomoko diagnosisprognosisandtreatmentofcaninehemangiosarcomaareviewbasedonaconsensusorganizedbythebrazilianassociationofveterinaryoncologyabrovet
AT decarvalhovasconcelloscarmenhelena diagnosisprognosisandtreatmentofcaninehemangiosarcomaareviewbasedonaconsensusorganizedbythebrazilianassociationofveterinaryoncologyabrovet
AT ubukatarodrigo diagnosisprognosisandtreatmentofcaninehemangiosarcomaareviewbasedonaconsensusorganizedbythebrazilianassociationofveterinaryoncologyabrovet
AT batschinskikaren diagnosisprognosisandtreatmentofcaninehemangiosarcomaareviewbasedonaconsensusorganizedbythebrazilianassociationofveterinaryoncologyabrovet
AT sobralrenataafonso diagnosisprognosisandtreatmentofcaninehemangiosarcomaareviewbasedonaconsensusorganizedbythebrazilianassociationofveterinaryoncologyabrovet
AT fernandessimonecrestoni diagnosisprognosisandtreatmentofcaninehemangiosarcomaareviewbasedonaconsensusorganizedbythebrazilianassociationofveterinaryoncologyabrovet
AT biondiluizroberto diagnosisprognosisandtreatmentofcaninehemangiosarcomaareviewbasedonaconsensusorganizedbythebrazilianassociationofveterinaryoncologyabrovet
AT defranciscostrefezziricardo diagnosisprognosisandtreatmentofcaninehemangiosarcomaareviewbasedonaconsensusorganizedbythebrazilianassociationofveterinaryoncologyabrovet
AT materajuliamaria diagnosisprognosisandtreatmentofcaninehemangiosarcomaareviewbasedonaconsensusorganizedbythebrazilianassociationofveterinaryoncologyabrovet
AT rangelmarcelomontemor diagnosisprognosisandtreatmentofcaninehemangiosarcomaareviewbasedonaconsensusorganizedbythebrazilianassociationofveterinaryoncologyabrovet
AT dosanjosdennersantos diagnosisprognosisandtreatmentofcaninehemangiosarcomaareviewbasedonaconsensusorganizedbythebrazilianassociationofveterinaryoncologyabrovet
AT brunnercarloshenriquemaciel diagnosisprognosisandtreatmentofcaninehemangiosarcomaareviewbasedonaconsensusorganizedbythebrazilianassociationofveterinaryoncologyabrovet
AT lauferamorimrenee diagnosisprognosisandtreatmentofcaninehemangiosarcomaareviewbasedonaconsensusorganizedbythebrazilianassociationofveterinaryoncologyabrovet
AT cadrobbikarinegermano diagnosisprognosisandtreatmentofcaninehemangiosarcomaareviewbasedonaconsensusorganizedbythebrazilianassociationofveterinaryoncologyabrovet
AT cirillojulianavieira diagnosisprognosisandtreatmentofcaninehemangiosarcomaareviewbasedonaconsensusorganizedbythebrazilianassociationofveterinaryoncologyabrovet
AT martinsmaurocaldas diagnosisprognosisandtreatmentofcaninehemangiosarcomaareviewbasedonaconsensusorganizedbythebrazilianassociationofveterinaryoncologyabrovet
AT depaulareisfilhonazilton diagnosisprognosisandtreatmentofcaninehemangiosarcomaareviewbasedonaconsensusorganizedbythebrazilianassociationofveterinaryoncologyabrovet
AT silvalessadiegofernando diagnosisprognosisandtreatmentofcaninehemangiosarcomaareviewbasedonaconsensusorganizedbythebrazilianassociationofveterinaryoncologyabrovet
AT portelaroberta diagnosisprognosisandtreatmentofcaninehemangiosarcomaareviewbasedonaconsensusorganizedbythebrazilianassociationofveterinaryoncologyabrovet
AT scarpacarneirocarolina diagnosisprognosisandtreatmentofcaninehemangiosarcomaareviewbasedonaconsensusorganizedbythebrazilianassociationofveterinaryoncologyabrovet
AT riccilucassilviaregina diagnosisprognosisandtreatmentofcaninehemangiosarcomaareviewbasedonaconsensusorganizedbythebrazilianassociationofveterinaryoncologyabrovet
AT fukumasuheidge diagnosisprognosisandtreatmentofcaninehemangiosarcomaareviewbasedonaconsensusorganizedbythebrazilianassociationofveterinaryoncologyabrovet
AT felicianomarcusantoniorossi diagnosisprognosisandtreatmentofcaninehemangiosarcomaareviewbasedonaconsensusorganizedbythebrazilianassociationofveterinaryoncologyabrovet
AT gomesquitzanjuliany diagnosisprognosisandtreatmentofcaninehemangiosarcomaareviewbasedonaconsensusorganizedbythebrazilianassociationofveterinaryoncologyabrovet
AT daglimarialuciazaidan diagnosisprognosisandtreatmentofcaninehemangiosarcomaareviewbasedonaconsensusorganizedbythebrazilianassociationofveterinaryoncologyabrovet